RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste.

While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...

RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...

A new paper published in Nature Biotechnology this week titled, “Template-independent enzymatic synthesis of RNA oligonucleotides,” provides details of a method for synthesizing single-stranded RNA ...

WATERTOWN, Mass.--(BUSINESS WIRE)--EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that co-founder and Chief ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A spinout from George Church’s ...

Researchers demonstrated how amino acids could spontaneously attach to RNA under early Earth-like conditions using thioesters, providing a long-sought clue to the origins of protein synthesis. This ...

WATERTOWN, Mass.--(BUSINESS WIRE)--EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, announced today that it is part of a ...